SHORT-TERM (4 WEEKS) SAFETY AND EFFICACY OF TENOFOVIR ALAFENAMIDE (TAF) COMPARED TO TENOFOVIR DISOPROXIL FUMARATE (TDF) AND ENTERCAVIR (ETV) IN TREATMENT-NAIVE ADULT PATIENTS WITH HBV-ACLF FROM SOUTH CHINA

被引：0

作者：

Peng, Liang ^{[1
]}

Wu, Lina ^{[1
]}

Zhang, Yeqiong ^{[1
]}

Zhu, Xiang ^{[1
]}

Li, Xuejun ^{[1
]}

Xu, Wenxiong ^{[1
]}

Zhen, Limin ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Dept Infect Dis, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China

来源：

HEPATOLOGY | 2019年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

492

引用

页码：311A / 312A

页数：2

共 39 条

[21] Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment
Buti, Maria
Izumi, Namiki
Lim, Young-Suk
Janssen, Harry
Kao, Jia-Horng
Streinu-Cercel, Adrian
Nurmukhametova, Elena
Ma, Xiaoli
Fehmi, Tabak
Jablkowski, Maciej
Suri, Vithika
Flaherty, John F.
Lau, Audrey
Gaggar, Anuj
Mo, Shuyuan
Chaudhuri, Abhijit
Fung, Scott
Chuang, Wan-Long
Gane, Edward
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E457 - E458
[22] Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B
Chan, Henry Lik Yuen
Lim, Young-Suk
Seto, Wai Kay Walter
Agarwal, Kosh
Brunetto, Maurizia R.
Janssen, Harry L. A.
Caruntu, Florin
Stepanova, Tatjana
Tsang, Owen
Yatsuhashi, Hiroshi
Tak, Won Young
Chen, Chi-Yi
Celen, Mustafa
Suri, Vithika
Flaherty, John F.
Lin, Lanjia
Cathcart, Andrea
Gaggar, Anuj
Pan, Calvin Q.
Shalimar
Buti, Maria
HEPATOLOGY, 2018, 68 : 227A - 228A
[23] Switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) or rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks
Orkin, C.
DeJesus, E.
Ramgopal, M.
Crofoot, G.
Ruane, P.
LaMarca, A.
Mills, A.
Van der Cam, B.
De Wet, J.
Rockstroh, J.
Lazzarin, A.
Rijnders, B.
Podzamczer, D.
Thalme, A.
Stoeckle, M.
Chu, H.
Porter, D.
Liu, H.
Cheng, A.
Quirk, E.
SenGupta, D.
Cao, H.
HIV MEDICINE, 2017, 18 : 21 - 21
[24] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) VS TENOFOVIR DISOPROXIL FUMARATE (TDF) IN EAST ASIAN CHRONIC HEPATITIS B PATIENTS FOLLOWING 5-YEARS OF TREATMENT
Wong, Grace Lai Hung
Gane, Edward
Pan, Calvin
Lim, Young-Suk
Fung, Scott
Izumi, Namiki
Ma, Mang
Chan, Carol Yee Kwan
Shalimar, Dr
Buti, Maria
GUT, 2021, 70 : A76 - A76
[25] CHRONIC HBV PATIENTS WHO SWITCHED TO TENOFOVIR ALAFENAMIDE (TAF) AFTER EITHER 2 OR 3 YEARS OF PRIOR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT DEMONSTRATED IMPROVEMENT IN BONE AND RENAL SAFETY
Buti, Maria
Izumi, Namiki
Lim, Young-Suk
Janssen, Harry L.
Kao, Jia-Horng
Streinu-Cercel, Adrian
Nurmukhametova, Elena
Ma, Xiaoli
Tabak, Omer
Jablkowski, Maciej
Suri, Vithika
Flaherty, John F.
Lau, Audrey H.
Gaggar, Anuj
Mo, Shuyuan
Chowdhury, Abhijit
Fung, Scott
Chuang, Wan-Long
Gane, Edward
GASTROENTEROLOGY, 2019, 156 (06) : S1195 - S1196
[26] A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy and safety results
Cheng, W.
Pianko, S.
Thompson, A.
Buti, M.
Gane, E.
Seto, W. K.
Chan, H. L. Y.
Chuang, W-L
Stepanova, T.
Hui, A-J
Lim, Y-S
Mehta, R.
Janssen, H.
Acharya, S. K.
Flaherty, J. F.
Massetto, B.
Cathcart, A.
Dinh, P.
Subramanian, G. M.
Mchutchison, J. G.
Pan, C.
Brunetto, M.
Izumi, N.
Marcellin, P.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 68 - 69
[27] Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults
Raffi, Francois
Orkin, Chloe
Clarke, Amanda
Slama, Laurence
Gallant, Joel
Daar, Eric
Yan, Mingjin
Abram, Michael E.
Friborg, Sandra
Cheng, Andrew
Rhee, Martin
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
[28] 96-WEEK EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) SWITCH VS. CONTINUED TDF TREATMENT AMONG VIROLOGICALLY-SUPPRESSED HEPATITIS B PATIENTS OF ASIAN ETHNICITY
Ahn, Sang Hoon
Kao, Jia-Horng
Lampertico, Pietro
Ramji, Alnoor
Fung, Scott
Chuang, Wan-Long
Kim, Yoon Jun
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Lee, June Sung
Chan, Carol Yee Kwan
Yee, Leland J.
Sethi, Shalini
Flaherty, John
Zhao, Yang
Gaggar, Anuj
Hann, Hie Won
Lim, Young-Suk
Chan, Henry Lik Yuen
GUT, 2021, 70 : A77 - A78
[29] A PHASE 3 STUDY COMPARING SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) WITH CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB): WEEK 48 EFFICACY AND SAFETY RESULTS
Chan, Henry Lik Yuen
Lampertico, Pietro
Buti, Maria
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Tak, Won Young
Ramji, Alnoor
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Flaherty, John
Gaggar, Anuj
Lau, Audrey
Feierbach, Becket
Wu, George
Suri, Vithika
Subramanian, Mani
Huy Trinh
Yoon, Seung-Kew
Agarwal, Kosh
Lim, Young-Suk
GUT, 2019, 68 : A142 - A143
[30] Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
Juan Li
Chunhua Hu
Yi Chen
Rou Zhang
Shan Fu
Mimi Zhou
Zhijie Gao
Mengjun Fu
Taotao Yan
Yuan Yang
Jianzhou Li
Jinfeng Liu
Tianyan Chen
Yingren Zhao
Yingli He
BMC Infectious Diseases, 21

← 1 2 3 4 →